Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock

Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.

The post Why It Could Soon Be Time To Take Profits In This Highflying Biotech Stock appeared first on Investor’s Business Daily.

Author: ALLISON GATLIN | Source

This article does not constitute investment advice. We are not affiliated or responsible for content hosted on 3rd-party sites in any way.

Click here for great deals & savings!